The biopharmaceutical industry is leading a period of unprecedented scientific progress with advances in the understanding and potential treatment of advanced cancers, Alzheimer’s and other neurodegenerative diseases. Coupled with scientific progress, our industry will be transformed by deeper and broader adoption of technology. Artificial intelligence fundamentally accelerates drug discovery and more rapidly identifies new biomarkers which can select sub-groups of patients more likely to respond to targeted therapies, thus advancing the potential of personalized medicine. The adoption of advanced analytics can accelerate the conduct of inclusive clinical trials for diverse patient populations representative of real-world epidemiology. Importantly, technology has the potential to accelerate the adoption of scientific advances in everyday clinical practice and address many of today’s health disparities. The discussion will focus on the areas of greatest potential for the industry and highlight the talent and culture implications of this transformation.